Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 76

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 2
Chunk 76
---
 access program called VEVYE Access for All. The program is designed to increase patient access to
VEVYE at an out-of-pocket cost of $59 or below and, in many cases, reduce the need for prior authorizations, step edits, and other treatment
obstacles facing dry eye patients and their prescribers.

Project
Beagle

During
the first quarter of 2025 we initiated a 360-degree review of opportunities to offer ImprimisRx customers a Harrow-owned FDA-approved
product alternative to a compounded formulation. We call this initiative Project Beagle. In that vein, we began implementing a continuity
of care program to transition approximately 25,000 ImprimisRx patients from our Klarity-C (0.1% cyclosporine) compounded formulation
to VEVYE (0.1% cyclosporine), and we discontinued compounding Klarity-C on June 30, 2025. We also discontinued another related compounded
formulation called Klarity PF. Klarity PF was primarily purchased by a concentrated group of customers who have accepted our FRESHKOTE
product as an alternative. We continue to review opportunities to reduce the size of our compounded formulary, improve and simplify our
compounding capabilities, and transition other ImprimisRx customers from compounded formulations to Harrow’s FDA-approved products.

Results
of Operations

The
following period-to-period comparisons of our financial results for the three and six months ended June 30, 2025 and 2024 are not necessarily
indicative of results for any future period.

31

Revenues

Our
revenues include amounts recorded from sales of proprietary compounded formulations, sales of branded products to wholesalers through
a third-party logistics facility, commissions from third parties and revenues received from royalty payments owed to us pursuant to out-license
arrangements.

The
following presents our revenues for the three and six months ended June 30, 2025 and 2024:

    For the
                                                                  Three Months Ended  
       
    For the
                                                                  Six Months Ended  

    June 30,  
       
    June 30,  
    $ 

    2025  
    2024  
    Variance  
    2025  
    2024  
    Variance 
  
    IHEEZO 
    $18,336,000  
    $11,295,000  
    $7,041